Thalidomide as an anti-cancer agent

Journal of Cellular and Molecular Medicine

Volumn 6, Issue 2, 2002, Pages 160-174

  Kumar, S ^a   Witzig, T E ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Anti neoplastic agent; Myeloma; Thalidomide; TNF alpha

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; BIOLOGICAL MODEL; BLOOD DISEASE; DRUG EFFECT; FORECASTING; HUMAN; METABOLISM; MULTIPLE MYELOMA; PALLIATIVE THERAPY; REVIEW; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; FORECASTING; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NEOVASCULARIZATION, PHYSIOLOGIC; PALLIATIVE CARE; T-LYMPHOCYTES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036549801     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. McBride W.G., Thalidomide and congenital abnormalities, Lancet, 2: 1358, 1961
2. McCredie J., Neural crest defects. A neuroanatomic basis for classification of multiple malformations related to phocomelia, J. Neurol. Sci., 28: 373, 1976
3. Lash J.W., Saxen L., Human teratogenesis: invitro studies on thalidomide-inhibited chondrogenesis, Dev. Biol., 28: 61, 1972
4. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis, Proceedings of the National Academy of Sciences of the United States of America, 91: 4082, 1994
5. Figg W.D., Raje S., Bauer K.S., Tompkins A., Venzon D., Bergan R., Chen A., Hamilton M., Pluda J., Reed E., Pharmacokinetics of thalidomide in an elderly prostate cancer population, J. Pharm. Sci., 88: 121, 1999
6. Piscitelli S.C., Figg W.D., Hahn B., Kelly G., Thomas S., Walker R.E., Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients, Antimicrob. Agents Chemother, 41: 2797, 1997
7. Eriksson T., Bjorkman S., Hoglund P., Clinical pharmacology of thalidomide, Eur. J. Clin. Pharmacol., 57: 365, 2001
8. Bauer K.S., Dixon S.C., Figg W.D., Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent, Biochemical Pharmacology, 55: 1827, 1998
9. Minchinton A.I., Fryer K.H., Wendt K.R., Clow K.A., Hayes M.M., The effect of thalidomide on experimental tumors and metastases, Anti Cancer Drugs, 7: 339, 1996
10. Folkman J., Tumor angiogenesis: therapeutic implications, N. Engl. J. Med., 285: 1182, 1971
11. Folkman J., Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis, New England Journal of Medicine, 333: 1757, 1995
12. Vermeulen P.B., Verhoeven D., Fierens H., Hubens G., Goovaerts G., Van Marck E., De Bruijn E.A., Van Oosterom A.T., Dirix L.Y., Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study, Br. J. Cancer, 71: 340, 1995
13. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., Gasparini G., Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma, J. Natl. Cancer Inst., 84: 1875, 1992
14. Dickinson A.J., Fox S.B., Persad R.A., Hollyer J., Sibley G.N., Harris A.L., Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas, British Journal of Urology, 74: 762, 1994
15. Rajkumar S.V., Leong T., Fonseca R., Dispenzieri A., Lacy M.Q., Witzig T.E., Lust J.A., Gertz M. A., Kyle R.A., Greipp P.R., Bone marrow angiogenesis has prognostic value in multiple myeloma. An Eastern Cooperative Oncology Group Study, Proc Am Soc Clin Oncol, 18: 19a, 1999
16. Bellamy W.T., Richter L., Frutiger Y., Grogan T. M., Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies, Cancer Research, 59: 728, 1999
17. Rajkumar S. V., Yoon S. Y., Li C. Y., Roche P. C., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., Gertz M.A., Kyle R.A., Greipp P.R., Witzig T.E., Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells, Blood, 94: 303b, 1999
18. Di Raimondo F., Azzaro M.P., Palumbo G., Bagnato S., Giustolisi G., Floridia P., Sortino G., Giustolisi R., Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood, Haematologica, 85: 800, 2000
19. Dankbar B., Padro T., Leo R., Feldmann B., Kropff M., Mesters R.M., Serve H., Berdel W. E., Kienast J., Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma, Blood, 95: 2630, 2000
20. Sezer O., Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma, European Journal of Haematology, 66: 83, 2001
21. Kumar S., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., Witzig T.E., Gertz M.A., Kyle R.A., Greipp P.R., Rajkumar S.V., Bone marrow (BM) angiogenesis in multiple myeloma (MM): effect of therapy and prognostic value, Blood, 96: 363a, 2000
22. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G., Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation, Journal of Experimental Medicine, 177: 1675, 1993
23. Niwayama S., Turk B. E., Liu J.O., Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides, J. Med. Chem., 39: 3044, 1996
24. Haslett P.A., Corral L.G., Albert M., Kaplan G., Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset, Journal of Experimental Medicine, 187: 1885, 1998
25. Gad S.M., Shannon E.J., Krotoski W.A., Hastings R.C., Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males, Lepr. Rev., 56: 35, 1985
26. McHugh S.M., Rifkin I.R., Deighton J., Wilson A. B., Lachmann P.J., Lockwood C.M., Ewan P.W., The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures, Clinical & Experimental Immunology, 99: 160, 1995
27. Geitz H., Handt S., Zwingenberger K., Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade, Immunopharmacology, 31: 213, 1996
28. Keifer J.A., Guttridge D.C., Ashburner B.P., Baldwin A.S., Jr., Inhibition of NF-kappa B activity by thalidomide through suppression of Ikappa B kinase activity, J. Biol. Chem., 276: 22382, 2001
29. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., Treon S.P., Lin B., Schlossman R.L., Richardson P., Muller G., Stirling D.I., Anderson K.C., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, Blood, 96: 2943, 2000
30. Noguchi T., Shimazawa R., Nagasawa K., Hashimoto Y., Thalidomide and its analogues as cyclooxygenase inhibitors, Bioorg. Med. Chem. Lett., 12: 1043, 2002
31. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., Lin B., Podar K., Gupta D., Chauhan D., Treon S.P., Richardson P.G., Schlossman R.L., Morgan G.J., Muller G.W., Stirling D.I., Anderson K.C., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, Blood, 98: 210, 2001
32. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J., Barlogie B., Antitumor activity of thalidomide in refractory multiple myeloma, New England Journal of Medicine, 341: 1565, 1999
33. Barlogie B., Spencer T., Tricot G., Zeldis J., Munshi N., Zangari M., Badros A., Toor A., Shaughnessy J., Morris C., Desikan R., Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM), Blood, 96: 514a, 2000
34. Rajkumar S. V., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., Witzig T.E., Kyle R.A., Gertz M. A., Greipp P.R., Thalidomide in the treatment of relapsed multiple myeloma, Mayo Clin. Proc., 75: 897, 2000
35. Rajkumar S.V., Dispenzieri A., Lacy M.Q., Geyer S., Itturia N., Fonseca R., Hayman S.R., Lust J. A., Kyle R.A., Greipp P.R., Gertz M.A., Witzig T. E., Response Rate and Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma (MM), Blood, 98: 162a, 2001
36. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., Badros A., Zangari M., Anaissie E., Epstein J., Shaughnessy J., Ayers D., Spoon D., Tricot G., Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients, Blood, 98: 492, 2001
37. Juliusson G., Celsing F., Turesson I., Lenhoff S., Adriansson M., Malm C., Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma, Br. J. Haematol., 109: 89, 2000
38. Grosbois B., Bellissant E., Moreau P., Attal M., Zerbib R., Thalidomide (Thai) in the Treatment of Advanced Multiple Myeloma (MM). A Prospective Study of 120 Patients, Blood, 98: Abstract 689, 2001
39. Hus M., Dmoszynska A., Soroka-Wojtaszko M., Jawniak D., Legiec W., Ciepnuch H., Hellmann A., Wolska-Smolen T., Skotnicki A., Manko J., Thalidomide treatment of resistant or relapsed multiple myeloma patients, Haematologica, 86: 404, 2001
40. Durie B., Stepan D.E., Low Dose Thalidomide Alone and in Combination: Long Term Follow-Up, Blood, 98: 163a, 2001
41. Bertolini F., Mingrone W., Alietti A., Ferrucci P. F., Cocorocchio E., Peccatori F., Cinieri S., Mancuso P., Corsini C., Burlini A., Zucca E., Martinelli G., Cineri S., Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers, Ann. Oncol., 12: 987, 2001
42. Raza S. N., Veksler Y., Sabir T., Li Z., Anderson L., Jagannath S., Durable response to thalidomide in relapsed/refractory multiple myeloma (MM), Blood, 96: 168a, 2000
43. Tosi P., Zamagni E., Cellini C., Ronconi S., Patriarca F., Ballerini F., Musto P., Di Raimondo F., Ledda A., Lauria F., Masini L., Gobbi M., Vacca A., Ria R., Cangini D., Tura S., Baccarani M., Cavo M., Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma, Haematologica, 87: 408, 2002
44. Schey S., Jones R. W., Cavenagh J., Johnson R., Thalidomide (T) in relapsed/refractory multiple myeloma (MM): a UK Myeloma Forum study: 6, 9, and 12-month results, Proc. ASCO: Abstract 1102, 2002
45. Alexanian R., Weber D., Giralt S., Delasalle K., Consolidation Therapy of Multiple Myeloma with Thalidomide-Dexamethasone after Intensive Chemotherapy, Blood, 98: Abstract 686, 2001
46. Dimopoulos M.A., Zomas A., Viniou N.A., Grigoraki V., Galani E., Matsouka C., Economou O., Anagnostopoulos N., Panayiotidis P., Treatment of Waldenstrom's macroglobulinemia with thalidomide, J. Clin. Oncol., 19: 3596, 2001
47. Seldin D.C., Choufani E., Skinner M., Wright D.G., Dember L., Weisman J., Fennessey S., Finn K., Sanchorwala V., A phase I/II trial of thalidomide for patients with AL amyloidosis, Blood, 98: Abstract 691, 2001
48. Steins M.B., Padro T., Bieker R., Ruiz S., Kropff M., Kienast J., Kessler T., Buechner T., Berdel W.E., Mesters R.M., Efficacy and safety of thalidomide in patients with acute myeloid leukemia, Blood, 99: 834, 2002
49. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., du Randt M., Kaspar C., Goldberg C., Loew J., Dar S., Gezer S., Venugopal P., Zeldis J., Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes, Blood, 98: 958, 2001
50. Zorat F., Shetty V., Dutt D., Lisak L., Nascimben F., Allampallam K., Dar S., York A., Gezer S., Venugopal P., Raza A., The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes, Br. J. Haematol., 115: 881, 2001
51. Barosi G., Grossi A., Comotti B., Marchetti M., Thalidomide in patients with myelofibrosis with myeloid metaplasia, Blood, 96: 746a, 2000
52. Pro B., Younes A., Albitar M., Hagemeister F. B., Rodriguez M.A., McLaughlin P., Clemons M., Samaniego F., Cabanillas F., Phase II study of thalidomide in patients with recurrent Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL), Blood, 98: Abstract 4712, 2001
53. Figg W. D., Dahut W., Duray P., Hamilton M., Tompkins A., Steinberg S.M., Jones E., Premkumar A., Linehan W.M., Floeter M.K., Chen C.C., Dixon S., Kohler D.R., Kruger E.A., Gubish E., Pluda J.M., Reed E., A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer, Clin. Cancer Res., 7: 1888, 2001
54. Figg W.D., Arlen P., Gulley J., Fernandez P., Noone M., Fedenko K., Hamilton M., Parker C., Kruger E.A., Pluda J., Dahut W.L., A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer, Semin. Oncol., 28: 62, 2001
55. Baidas S.M., Winer E.P., Fleming G.F., Harris L., Pluda J.M., Crawford J.G., Yamauchi H., Isaacs C., Hanfelt J., Tefft M., Flockhart D., Johnson M.D., Hawkins M.J., Lippman M.E., Hayes D.F., Phase II evaluation of thalidomide in patients with metastatic breast cancer, J. Clin. Oncol., 18: 2710, 2000
56. Fife K., Howard M.R., Gracie F., Phillips R.H., Bower M., Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre, Int. J. STD. AIDS, 9: 751, 1998
57. Fine H.A., Figg W.D., Jaeckle K., Wen P.Y., Kyritsis A.P., Loeffler J.S., Levin V.A., Black P. M., Kaplan R., Pluda J.M., Yung W.K., Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas, J. Clin. Oncol., 18: 708, 2000
58. Hwu W.J., Krown S.E., Menell J.H., Panageas K.S., Merrell J., Quinn C.J., Chapman P.B., Livingston P.O., Wolchok J.D., Williams L.J., Houghton A.N., Temozolomide (TMZ) plus thalidomide in patients with advanced melanoma: a phase II trial, Proc. ASCO: Abstract 1372, 2002
59. Govindarajan R., Irinotecan and thalidomide in metastatic colorectal cancer, Oncology (Huntingt), 14: 29, 2000
60. Richardson P.G., Schlossman R.L., Hideshima T., Davies F., LeBlanc R., Catley L., Doss D., Kelly K.A., McKenney M., Mechlowicz J., Freeman A., Deocampo R., Rich R., Ryoo J., Chauhan D., Munshi N., Weller E., Thomas S., Zeldis J., Anderson K.C., A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). Blood, 98: 775a, 2001
61. Elliott M. A., Mesa R. A., Li C. Y., Hook C. C., Ansell S. M., Levitt R. M., Geyer S. M., Tefferi A., Thalidomide treatment in myelofibrosis with myeloid metaplasia, Br. J. Haematol., 117: 288, 2002
62. Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L., Johnston S.R., Ahern R., Smith I.E., Gore M.E., Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer, Br. J. Cancer, 82: 812, 2000
63. Little R.F., Wyvill K.M., Pluda J.M., Welles L., Marshall V., Figg W.D., Newcomb F.M., Tosato G., Feigal E., Steinberg S.M., Whitby D., Goedert J.J., Yarchoan R., Activity of thalidomide in AIDS-related Kaposi's sarcoma, J. Clin. Oncol., 18: 2593, 2000
64. Stebbing J., Benson C., Eisen T., Pyle L., Smalley K., Bridle H., Mak I., Sapunar F., Ahern R., Gore M. E., The treatment of advanced renal cell cancer with high-dose oral thalidomide, Br. J. Cancer, 85: 953, 2001
65. Motzer R.J., Berg W., Ginsberg M., Russo P., Vuky J., Yu R., Bacik J., Mazumdar M., Phase II trial of thalidomide for patients with advanced renal cell carcinoma, J. Clin. Oncol., 20: 302, 2002
66. Short S.C., Traish D., Dowe A., Hines F., Gore M., Brada M., Thalidomide as an anti-angiogenic agent in relapsed gliomas, J. Neurooncol., 51: 41, 2001
67. Marx G.M., Pavlakis N., McCowatt S., Boyle F. M., Levi J.A., Bell D.R., Cook R., Biggs M., Little N., Wheeler H.R., Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme, J. Neurooncol., 54: 31, 2001